

Phenotypic and Molecular Characterization of Multidrug Resistant Gram-Negative Organisms from Lower Respiratory Tract Infections: A Review

Puvvada Sai Swaroop¹, Dhruba Hari Chandi², Ranjit Ambad³

¹Assistant Professor and PhD Scholar Dept. of Microbiology Jawaharlal Nehru Medical College, DMIHER Wardha

²Associate Professor Dept. of Microbiology Jawaharlal Nehru Medical College, DMIHER Wardha

³Professor, Department of Biochemistry, Jawaharlal Nehru Medical College, DMIHER, Sawangi (Meghe), Wardha

Corresponding author:

Puvvada Sai Swaroop

Email.id. swaroop8288@gmail.com

ABSTRACT

Lower respiratory tract infections (LRTIs) remain among the leading causes of morbidity and mortality worldwide, particularly in immunocompromised and hospitalized patients. The emergence of multidrug resistant (MDR) Gram-negative bacteria such as *Klebsiella pneumoniae*, *Pseudomonas aeruginosa*, *Acinetobacter baumannii*, and *Escherichia coli* has further complicated clinical management. Conventional phenotypic antimicrobial susceptibility testing (AST) provides essential guidance but fails to capture the complete resistance landscape. Molecular approaches, including PCR-based detection of resistance genes, offer greater precision in identifying extended-spectrum β -lactamases (ESBLs) and carbapenemases. This review synthesizes current evidence on phenotypic and molecular characterization of MDR Gram-negative bacteria in LRTIs, emphasizing their epidemiology, mechanisms of resistance, diagnostic approaches, and clinical implications.

Keywords: Multidrug resistance; Gram-negative bacteria; Lower respiratory tract infections; phenotypic characterization; Molecular characterization; Antimicrobial resistance genes and ESBL.

How to Cite: Puvvada Sai Swaroop, Dhruba Hari Chandi, Ranjit Ambad, (2025) Phenotypic and Molecular Characterization of Multidrug Resistant Gram-Negative Organisms from Lower Respiratory Tract Infections: A Review, Vascular and Endovascular Review, Vol.8, No.2s, 298-300.

INTRODUCTION

Lower respiratory tract infections (LRTIs) remain a leading cause of morbidity and mortality worldwide, particularly among hospitalized and critically ill patients (1). Gram-negative organisms — notably *Klebsiella pneumoniae*, *Escherichia coli*, *Pseudomonas aeruginosa* and *Acinetobacter baumannii* — are frequent causes of community-acquired and hospital-acquired LRTIs (2). The rising prevalence of multidrug resistance (MDR) among these pathogens has seriously narrowed therapeutic options, increased lengths of stay, raised healthcare costs, and worsened patient outcomes (3). Understanding both the phenotypic behaviour and the underlying molecular mechanisms of resistance is therefore essential for effective treatment, infection control, and surveillance (4).

Phenotypic characterization provides the first, clinically actionable layer of information. Conventional culture and identification followed by antimicrobial susceptibility testing (AST) — using disc diffusion, broth microdilution, or automated systems — determine which agents remain active against an isolate and guide immediate therapy. Additional phenotypic assays (for example, combined disk tests, inhibitor-based methods, Modified Hodge/Carba NP tests, and screening for extended-spectrum β -lactamase [ESBL], AmpC, metallo- β -lactamase [MBL] or carbapenemase activity) help classify resistance phenotypes and detect important enzymatic mechanisms that may not be obvious from routine AST alone (5).

Molecular characterization complements phenotype by identifying the genetic determinants that drive resistance, their genetic context (plasmids, transposons, integrons), and the potential for horizontal transfer. Polymerase chain reaction (PCR) assays and targeted gene sequencing detect key resistance genes such as blaCTX-M, blaSHV, blaTEM (ESBLs), blaAmpC, and carbapenemase genes (blaNDM, blaKPC, blaVIM, blaIMP, blaOXA-48-like). More comprehensive approaches — multilocus sequence typing (MLST), plasmid replicon typing, and whole-genome sequencing (WGS) — enable high-resolution epidemiology, uncover clonal spread, trace transmission pathways, and reveal novel or emerging resistance mechanisms (6).

This review synthesizes current knowledge on the phenotypic and molecular characterization of MDR Gram-negative organisms isolated from LRTIs. We summarize common phenotypic methods and their limitations, outline the principal genetic determinants and mobile elements responsible for resistance, discuss the clinical and epidemiological implications, and highlight gaps in diagnostics and surveillance that should guide future research and policy.

,

MATERIAL AND METHOD

This review was conducted using a systematic approach to identify relevant studies on phenotypic and molecular characterization of multidrug-resistant (MDR) Gram-negative organisms isolated from lower respiratory tract infections (LRTIs). A comprehensive search was performed in major electronic databases including PubMed, Scopus, Web of Science, Google Scholar, and Science Direct. The search covered studies published between 2017 to till date.

OBSERVATION AND DISCUSSION

Phenotypic Characterization of MDR Gram-Negative Organisms

Across the reviewed studies, Enterobacterales (particularly *Klebsiella pneumoniae* and *Escherichia coli*), along with *Pseudomonas aeruginosa* and *Acinetobacter baumannii*, emerged as the predominant Gram-negative pathogens isolated from lower respiratory tract infections (LRTIs). Routine antimicrobial susceptibility testing consistently demonstrated high levels of resistance to β -lactams, fluoroquinolones, and aminoglycosides, while carbapenem resistance was increasingly reported, especially among *K. pneumoniae* and *A. baumannii* (7).

Phenotypic assays such as combined disc tests, inhibitor-based methods, Modified Hodge Test, Carba NP test, and EDTA-based assays were frequently employed for the detection of extended-spectrum β -lactamase (ESBLs), AmpC β -lactamases, and carbapenemases. While these methods are relatively inexpensive and widely available, their sensitivity and specificity vary, and in some cases, overlapping resistance mechanisms complicated interpretation. For example, co-production of ESBLs and AmpC enzymes may mask phenotypic detection, leading to underestimation of resistance burden (8).

Molecular Characterization and Resistance Genes

Molecular approaches provided greater precision in identifying the genetic basis of resistance. PCR and sequencing revealed widespread distribution of bla genes, notably blaCTX-M, blaSHV, and blaTEM in Enterobacterales, while blaNDM, blaKPC, blaVIM, blaIMP, and blaOXA-48-like genes were commonly reported in carbapenem-resistant isolates (9).

In *P. aeruginosa* and *A. baumannii*, carbapenem resistance was often associated with blaOXA-type enzymes and metallo- β -lactamases, alongside efflux pump overexpression and porin loss, which were not always evident in phenotypic assays. Advanced molecular techniques such as multilocus sequence typing (MLST) and whole-genome sequencing (WGS) revealed the clonal spread of high-risk lineages (e.g., *K. pneumoniae* ST258, *A. baumannii* international clones), emphasizing the role of genetic epidemiology in outbreak investigations (10).

Correlation Between Phenotypic and Molecular Methods

A recurring observation was the discordance between phenotypic and molecular findings. Some isolates carried resistance genes without expressing them phenotypically, while others exhibited resistance due to mechanisms not easily detected by standard PCR panels (e.g., efflux pump upregulation). This highlights the need for an integrated approach, where phenotypic susceptibility guides immediate therapy, and molecular diagnostics provide confirmatory evidence and insights into transmission dynamics (11).

Clinical and Epidemiological Implications

The high prevalence of MDR Gram-negative pathogens in LRTIs significantly limits treatment options, often leaving colistin and a few novel β -lactam/ β -lactamase inhibitor combinations as last-resort therapies. Molecular evidence of plasmid-mediated gene transfer indicates a high potential for rapid dissemination of resistance determinants across species and healthcare settings. These findings underscore the importance of antimicrobial stewardship, strict infection control measures, and continuous molecular surveillance to prevent outbreaks (12).

CONCLUSION

Multidrug-resistant Gram-negative organisms represent a major challenge in the management of lower respiratory tract infections, contributing to prolonged illness, limited therapeutic options, and increased mortality. An integrated approach that combines phenotypic susceptibility testing with molecular diagnostics offers the most comprehensive understanding of resistance, enabling better clinical decision-making, outbreak detection, and infection control. Strengthening laboratory capacity, promoting antimicrobial stewardship, and implementing molecular surveillance programs are crucial steps toward curbing the spread of multidrug resistance.

REFERENCES

1. Sajjad A, Anwar MS, Malik A, et al. Phenotypic detection of ESBL and AmpC β -lactamase among clinical isolates of Enterobacteriaceae. *Int J Med Microbiol Trop Dis*. 2025;10(2):xxx-xxx.
2. Assefa M. Multi-drug resistant gram-negative bacterial pneumonia: etiology, risk factors, and drug resistance patterns. *Pneumonia* (Nathan). 2022 May 5;14(1):4. doi: 10.1186/s41479-022-00096-z. PMID: 35509063; PMCID: PMC9069761.

3. Salam MA, Al-Amin MY, Salam MT, Pawar JS, Akhter N, Rabaan AA, Alqumber MAA. Antimicrobial Resistance: A Growing Serious Threat for Global Public Health. *Healthcare (Basel)*. 2023 Jul 5;11(13):1946. doi: 10.3390/healthcare11131946. PMID: 37444780; PMCID: PMC10340576.
4. Munita JM, Arias CA. Mechanisms of Antibiotic Resistance. *Microbiol Spectr*. 2016 Apr;4(2):10.1128/microbiolspec.VMBF-0016-2015. doi: 10.1128/microbiolspec.VMBF-0016-2015. PMID: 27227291; PMCID: PMC4888801.
5. Gajic I, Kabic J, Kekic D, Jovicevic M, Milenkovic M, Mitic Culafic D, Trudic A, Ranin L, Opavski N. Antimicrobial Susceptibility Testing: A Comprehensive Review of Currently Used Methods. *Antibiotics (Basel)*. 2022 Mar 23;11(4):427. doi: 10.3390/antibiotics11040427. PMID: 35453179; PMCID: PMC9024665.
6. Sultan, Insha & Siddiqui, Mohammad Tahir & Gogry, Firdoos & Haq, Qazi. (2022). Molecular characterization of resistance determinants and mobile genetic elements of ESBL producing multidrug-resistant bacteria from freshwater lakes in Kashmir, India. *Science of The Total Environment*. 827. 154221. 10.1016/j.scitotenv.2022.154221.
7. Balkhair A, Saadi KA, Adawi BA. Epidemiology and mortality outcome of carbapenem- and colistin-resistant *Klebsiella pneumoniae*, *Escherichia coli*, *Acinetobacter baumannii*, and *Pseudomonas aeruginosa* bloodstream infections. *IJID Reg*. 2023 Jan 8;7:1-5. doi: 10.1016/j.ijregi.2023.01.002. PMID: 36936715; PMCID: PMC10014253.
8. Aruhomukama D. Review of phenotypic assays for detection of extended-spectrum β -lactamases and carbapenemases: a microbiology laboratory bench guide. *Afr Health Sci*. 2020 Sep;20(3):1090-1108. doi: 10.4314/ahs.v20i3.11. PMID: 33402954; PMCID: PMC7751514.
9. Ibrahim ME, Algak TB, Abbas M, Elamin BK. Emergence of blaTEM, blaCTX-M, blaSHV and blaOXA genes in multidrug-resistant Enterobacteriaceae and *Acinetobacter baumannii* in Saudi Arabia. *Exp Ther Med*. 2021 Dec;22(6):1450. doi: 10.3892/etm.2021.10885. Epub 2021 Oct 14. PMID: 34721692; PMCID: PMC8549092.
10. Słoczyńska, A., Wand, M. E., Bock, L. J., Tyski, S., & Laudy, A. E. (2023). Efflux-Related Carbapenem Resistance in *Acinetobacter baumannii* Is Associated with Two-Component Regulatory Efflux Systems' Alteration and Insertion of Δ AbaR25-Type Island Fragment. *International Journal of Molecular Sciences*, 24(11), 9525. <https://doi.org/10.3390/ijms24119525>
11. Al-Mutairi NM, Ahmad S, Mokaddas E. Discordance in Phenotypic and Genotypic Susceptibility Testing for Streptomycin Due to Nonsynonymous/Nonsense/Deletion Frame-Shift Mutations in Gidb Among Clinical *Mycobacterium tuberculosis* Isolates in Kuwait. *Med Princ Pract*. 2024 Apr 1;33(4):321–9. doi: 10.1159/000538584. Epub ahead of print. PMID: 38560979; PMCID: PMC11324218.
12. Mondal, A. H., Khare, K., Saxena, P., Debnath, P., Mukhopadhyay, K., & Yadav, D. (2024). A Review on Colistin Resistance: An Antibiotic of Last Resort. *Microorganisms*, 12(4), 772. <https://doi.org/10.3390/microorganisms12040772>